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Abstract
Introduction: Tissue cryoablation is a potential curative option for solid malignancies, including radiation recurrent prostate
cancer (RRPC). Case series of salvage cryotherapy (SCT) in RRPC have reported promising disease free survival (DFS)
outcomes and acceptable toxicity profile. While many men receive SCT, no predictive factors for treatment induced side
effects are known. The aim of this study is to validate the oncologic outcome of SCT in a large multi-centre patient cohort
and to identify potential parameters associated with an increased risk of micturition symptoms.
Patients and Methods: In this retrospective analysis, we studied 283 consecutive patients with RRPC treated by SCT in three
independent U.K. centres (between 2001 and 2011). Two freeze-thaw cycles of transperineal cryotherapy were performed
under transrectal ultrasound guidance by a single surgeon in each of the 3 sites. We analysed clinico-pathological factors
against tumour response. Functional outcomes were assessed by continence status and IPSS questionnaire. Predictive
factors for SCT-induced micturition symptoms were analysed in a sub-group (n = 42) of consecutive cases.
Results: We found that nadir post-SCT PSA levels strongly associated with DFS. The DFS rates at 12- and 36-month were
84% and 67% for the #1 ng/ml group and 56% and 14% for the .1 ng/ml group, respectively (p,0.001). Correlative
analysis revealed highly significant association between patients’ post-SCT micturition status with prostate gland and iceball
lengths following SCT. Finally, in a reduction model, both gland length and maximal length of iceball were highly associated
with patients’ IPSS outcome (p,0.001).
Conclusion: We report the largest European patient cohort treated with SCT for RRPC. Oncologic outcome guided by nadir
PSA of ,1 ng/ml is consistent with earlier single-centre series. For the first time, we identified physical parameters to
predict micturition symptoms following SCT. Our data will directly assist on-going and future trial design in cryotherapy in
prostate cancer.
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Introduction
Recurrence following radiotherapy (RT) is a difficult treatment
dilemma, which is not uncommon amongst prostate cancer (PC)
patients. Over 30% of patients are reported to develop cancer
recurrence following primary RT [1], with most of these patients
managed by androgen deprivation therapy (ADT). Salvage radical
prostatectomy (RP) is far more challenging than primary RP [2–
5], with radiation induced vasculitis, fibrosis and tissue plane
obliteration leading to significant risk of rectal injuries, anasto-
motic strictures and urinary incontinence while positive margin
rates can be over 50% [2,6]. Despite this, in the younger patient,
salvage RP offers superior biochemical disease-free survival and
may potentially offer the best chance of cure [7].
Taking this into consideration, local ablative treatments such as
salvage cryotherapy (SCT) and high-intensity focused ultrasound
(HIFU) are increasingly considered as viable options for second
line therapies with intent for cure. However these minimally
invasive procedures are not without potential risks of serious
treatment related toxicities, including genito-urinary symptoms,
erectile failure and less commonly rectal injury [8]. Overall, these
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Figure 1. PSA and Gleason sum scores of SCT population. (a) Dot blot showing the pre and post-SCT nadir PSA for the entire patient cohort,
(b) Bar chart representing the numbers of patients with different Gleason sum scores prior to SCT.
doi:10.1371/journal.pone.0069243.g001
Figure 2. Disease free survival by (a) Pre-SCT PSA, (b) Gleason Score and (c) PSA nadir.
doi:10.1371/journal.pone.0069243.g002
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risks are considered acceptable, with disease free survival (DFS) of
up to 56% and 39% at 5-years and 10-years following SCT,
respectively [8–11]. While treatment related toxicities are often
reported, little is known about the relative risk factors among
individual patients undergoing the procedure. Here, we reported
our multi-centre case series and considered factors that directly
impact on the risk of side effects as well as treatment efficacy.
Materials and Methods
Trial Registration
http://public.ukcrn.org.uk, CROP Trial, URL: http://public.
ukcrn.org.uk/Search/StudyDetail.aspx?StudyID =10051.
Patients, follow up and data collection
All patients who underwent SCT for radiation recurrent
prostate cancer between 2001–2011 at the three participating
U.K. centres were included, namely Glasgow (Gartnavel General
Hospital), Sunderland (Sunderland Royal Hospital), and Guildford
(the Royal Surrey County Hospital). Patients were selected based
on evidence of primary RT failure and histologic evidence of
localised PC in the absence of metastatic disease (negative MRI
and isotopic bone scan).
Patients were initially followed up by PSA monitoring at
6 weeks, then 3 monthly intervals till 12 months, followed by
6 monthly, up to a maximum of 72 months. Data collected
included patient age, PSA levels before SCT, clinical stage, biopsy
Gleason score, follow up PSA levels and survival status as well as
results from bone scan, CT and MRI. Recurrence was defined
using the Phoenix definition of nadir plus 2 ng/ml as well as
radiological, histological, or clinical evidence of recurrent prostate
cancer. Disease free survival (DFS) was defined as the time in
months from SCT to date of recurrence. Patient functional
outcomes were assessed by the following parameters: continence
status (use of #1 or $2 pads per day), IPSS total score of 7
symptoms (range 0–35) and IPSS quality of life score (range 1–6).
Prostate cryoablation and data on physical parameters
SCT was performed as described previously [12,13]. In brief,
cryoablation of the prostate gland was performed using the
SeednetTM/PresiceTM (GalilMedical, Plymouth Meeting, PA,
USA) or the Cryocare CS system (Endocare, Inc., Irvine, CA,
USA). Cryo-needles are inserted into three imaginary levels into
the prostate; anterior, middle and posterior. Thermocouples are
placed in critical positions to monitor the temperature of the
anterior rectal wall and the adjacent structure including the
sphincter. Each freeze cycle was started with the anterior needles;
once the entire width of the prostate was covered anteriorly, the
middle and then the posterior row of cryoneedles were switched
on. Two cycles of freezing and thawing were performed to
published consensus [14] with lowest temperature within the
prostate to below 230uC to 240uC for 5–10 minutes. Real time
assessment of the dimension and contour of iceballs was performed
using transrectal ultrasonography in sagittal and coronal views.
A cohort of consecutive patients (n = 42) treated in Glasgow
between 2008–2011 were analysed for relationship between
physical parameters of cryoablation (temperature achieved and
iceball length). Data were collected for (1) the lowest temperature
obtained in each lobe of the prostate, (2) the longitudinal length of
the iceball (parallel to the anterior rectal wall) at the end of each
freeze cycle, and (3) the prostatic gland length.
Statistics and correlative analysis
Chi-squared tests were used for grouped data and Student t tests
for continuous data. Statistical analyses on clinico-pathologic
correlations and disease free survival were performed using Prism
v5.0c (GraphPad Software Inc., La Jolia, CA, USA). Univariate
and multivariate generalized linear models (glm) with Poisson
response were used to test effects of the physical parameters from
cryoablation on post-SCT IPSS values, taking into consideration
of the skewed distribution of positive discrete values of IPSS. For
multiple IPSS values of individual cases, minimum, maximum and
mean, rounded up to the nearest whole number, were considered
in the analysis. First, full list of predictors was considered in a
multivariate model. Then, using the automated model selection
package ‘glmulti’ from R environment (http://www.r-project.org),
all possible reduced model formulae were generated and the ‘best’
models, based on Akaike information criterion (AIC), were
selected. Finally, we focused on model(s) that had a simple
explanation and possible clinical application.
Table 1. Summary demographics of our series of patients
who received SCT.
Age at time of Rx Number of Patients
(Percentage in bracket)
#65 130 (45.5%)
.65 153 (54.5%)
Pre Rx Gleason
,7 53 (21.4%)
7 108 (43.5%)
.7 87 (35.1%)
Pre Rx PSA, ng/dl
,5 120 (49.2%)
05-Oct 74 (30.3%)
.10 50 (20.5%)
Clinical T Score
T1 20 (9.3%)
T2 134 (62.0%)
T3/4 62 (28.7%)
Breakdown of patient demographics and tumour parameters from the three
cryotherapy centres can be found in Table S1. Please note that not all
categories add up to 283, since data was incomplete for some patients as
regards Pre Rx Gleason, Pre Rx PSA and Clinical T score. (Rx = cryotherapy).
doi:10.1371/journal.pone.0069243.t001
Table 2. Post-SCT complications and the number of patients
affected by each complication.
Complication Number %
Urinary Incontinence 37 12
Erectile Dysfunction 246 83
Lower Urinary Tract Symptoms 42 14
Prolonged Perineal Pain 11 4
Urinary Retention 20 7
Recto-Urethral Fistula 5 1.8
doi:10.1371/journal.pone.0069243.t002
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Ethics
Prostate cryotherapy is a clinically valid treatment option for
radiation recurrent prostate cancer. There are no ethical issues
with the reported study.
Results
Analysis of treatment efficacy
Pre-SCT demographic patient information (n= 283) is summa-
rised in Tables 1 and S1. Patients with data on the three specific
risk factors were included in the analysis, namely pre-SCT PSA
(n = 197), pre-SCT Gleason score (n = 195) and post-SCT nadir
PSA (n= 227) (Figures 1, S1, S2). Patients were followed up for an
average of 23.9 months (IQR 3–36 months). Contrary to previous
reports on SCT, our patients with a pre-SCT PSA of ,5, 5–10
and .10 ng/ml had very similar 12-month disease free survival
(DFS) rates, at 78%, 76% and 73% respectively [10]. At 5-year,
patients with PSA up to 10 ng/ml had DFS rates of ,55%, while
those with PSA .10 ng/ml had DFS rate slightly lower at 44%
(not statistically different: p = 0.367, log rank test; Figure 2a and
Table S2). A similar analysis of Gleason score showed some
variability in the DFS rates for patients with scores of ,7, = 7 and
.7, with 12-month DFS rates at 85%, 76% and 65%,
respectively, and 5-year DFS rates at 71%, 42% and 44%,
respectively. A log rank test indicated that the hazard functions for
these three groups were not statistically different at the 5%
significance level (p = 0.106; Figure 2b and Table S2).
Consistent with a recent single centre report [10], the DFS rates
in our patient cohort were significantly different at the 5%
significance level when patients were stratified according to their
post-SCT nadir PSA levels into #1 and .1 ng/ml groups. The
12-month and 36-month DFS rates were 84% and 67% for the
#1 ng/ml group and 56% and 14% for the .1 ng/ml group
respectively. A log rank test indicated that the hazard functions
were statistically different at the 5% significance level (p,0.001)
(Figure 2c and Table S2).
Functional outcome and correlative analysis of
cryotherapy parameters
Functional outcomes of our series are comparable to previously
published literature, with incontinence rates up to 36% and fistula
rates up to 2.6% being reported [9,15–17]. We observed long-
term incontinence rates of 12% (using .1 pad per day beyond
6 months post-SCT) and fistula rate of 1.8%, highlighting the
acceptability of this salvage modality. Our erectile dysfunction
(ED) rate was at 83%, although at least half of these patients had
some form of pre-existing ED, Table 2. We observed a statistically
significant change in the international prostate symptom score
(IPSS), with scores increasing (or symptoms worsening) after SCT
(Paired t-test, p,0.0001) (Figure S3). A total of 23 patients out of
the 283 (8.1%) treated patients required transurethral resection of
the prostate for obstructive urinary symptoms.
We hypothesised that treatment related toxicities such as
incontinence following SCT directly relate to the dimensions of
prostate gland and iceball generated. Therefore, we carried out
statistical modeling to investigate for correlation between physical
parameters (temperature and iceball dimensions) and patient
functional status (incontinence and micturition functional scores as
assessed by IPSS) in a cohort of 42 consecutive patients. Full set of
data on prostate gland lengths and physical parameters from
cryotherapy procedures were available on 31 patients, including
minimal temperatures within the prostate achieved and iceball
lengths at the end of each freeze cycles. Multivariate analysis of
these parameters revealed highly significant association between
patients’ post-SCT IPSS (both mean and maximal) scores with
gland and iceball lengths at the end of first and second cycle of
Table 3. Summary of multivariate analysis.
Parameters Mean Std. Dev. n Multivariate (Mean IPSS); p values Multivariate (Max IPSS); p values
Right_Lobe_1_C 43.6 14.24 35 0.45094 0.27733
Right_Lobe_2_C 39.9714 12.8761 35 0.999 0.700769
Left_Lobe_1_C 38.6286 17.8162 35 0.68923 0.327031
Left_Lobe_2_C 33.8529 12.702 34 0.34296 0.108465
Gland_Length 32.6857 3.80226 35 4.35E-05 3.20E-06
Iceball_Length_ 1_C 37 2.72915 30 0.17239 0.060049
Iceball_Length_ 2_C 36.9677 3.58221 31 0.00178 0.000642
Multivariate analysis of SCT parameters reveals highly significant association between dimensions of gland length and the iceball with patients’ IPSS scores. (1_C and
2_C denotes 1st and 2nd cycles, respectively; Right and left lobe signified the nadir temperature recorded below 0uC; Iceball Length signifies the dimension of iceball
parallel to the anterior rectal wall, measured in mm, at the end of each freeze cycle; n = patient numbers).
doi:10.1371/journal.pone.0069243.t003
Table 4. Simplified analysis of gland length and the largest iceball dimension against IPSS scores.
Parameters Mean Std. Dev. n Multivariate (Mean IPSS); p values Multivariate (Max IPSS); p values
Gland_Length 32.6857 3.80226 35 0.02417 0.00645
Iceball_Length_ 1_C 37 2.72915 30 0.47602 0.86751
Iceball_Length_ 2_C 36.9677 3.58221 31 0.00604 0.00284
Significant association between gland length and iceball length with (mean and maximal) IPSS scores were observed. (1_C and 2_C denotes 1st and 2nd cycles,
respectively; n = patient numbers).
doi:10.1371/journal.pone.0069243.t004
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freezing (Table 3). The absolute minimal temperatures recorded
within the prostate were interestingly not associated with IPSS
scores. We carried out additional multivariate analysis of the best
reduced-model from the ‘glmulti’ selection. Table 4 demonstrates
a highly significant association between gland length and ice
length following the second freeze cycle. To develop a simple
platform for correlative analysis in future studies, IPSS scores were
analysed against a single minimal temperature and the maximal
iceball length for each cryotherapy procedure as well as the
respective gland length. We found gland length and maximal
iceball length to be highly associated with individual patients’ IPSS
outcome (Table 5). It is likely that the relative lengths of individual
prostate length and the respective iceball size may determine the
actual risk to the surrounding tissue. We therefore examined if the
ratio of the iceball dimension and the prostate length is related to
patient outcome. While not reaching statistical significance, a
trend was observed. Two of the twenty (10%) cases with ratio of
MaxIceball/gland below 1.2 has IPSS .20 while 5 out of 11 cases
(45%) with ratio above 1.2 has IPSS .20. Finally, we found no
evidence of association between patient continence status and
prostatic temperature or iceball length.
Discussion
The published literature on the incidence of genitourinary
toxicity following SCT is highly variable. The underlying basis for
such widely varied functional outcome has not been adequately
considered. Here, we report the largest European patient cohort
treated with SCT for radiation recurrent prostate cancer (RRPC).
It is worth noting that patients who received androgen ablation in
conjunction with SCT were excluded from this study. Our toxicity
outcome data (Table 2) are in keeping with reported literatures,
further supporting SCT as an acceptable treatment for radiation
recurrent PC. To our knowledge, this is the first study successfully
attempted to identify potential means to objectively assess and
predict the risk of treatment toxicity following local cryoablative
treatment in any organs. This will impact the applications of
cryotherapy to different tumour types in both primary and salvage
treatment settings. We collected physical parameters during SCT
procedures and tested for their association with symptomatology
related to micturition function. We found significant associations
between dimensions of the prostate gland and iceball on one hand
and IPSS scores on the other hand (Table 3–5). Interestingly, the
absolute minimal temperatures recorded within the prostate did
not correlate with IPSS scores. Conceptually, it is clearly logical
that the relative prostate gland size and iceball dimension may
correlate with functional outcome, with the sphincteric muscle
being at high risk of freeze injury if the iceball expands beyond the
physical dimension of the prostate gland during cryotherapy. Our
findings will impact on future refinement of SCT techniques in
ensuring optimal treatment efficacy while minimising toxicities due
to freezing injury to adjacent tissue. The approach for analysis
presented in this report provides a simple but objective method-
ology to prospectively assess individuals’ risk in experiencing
significant urinary symptoms and should be incorporated in
prospective cryotherapy studies [18,19]. Though not reaching
statistical significance, based on our data, an iceball extending
significantly beyond the prostatic gland length (ratio of .1.2 fold)
may result in higher risk of micturition-related toxicities. Our
current working model is that patients with glandular size such as
between 20–30 cm3 are ideal for total prostatic cryoablation. Our
reasoning is that, when treating patients with a moderate prostatic
dimension, the cryotherapy practitioners may have the best
chance in achieving therapeutic level of freezing while maintaining
a ratio between iceball to prostate lengths to below 1.2. This
hypothesis requires further investigation in future (prospective)
studies.
Although consecutive patients were included in this multi-
institute study, an important limiting factor is its retrospective
nature, with heterogeneous within the patient populations [10,20].
The impact of nadir PSA as an indicator of treatment response is
consistent with other recent publications. Those patients with a
high PSA nadir following SCT (.1 ng/ml and $0.6 ng/ml
respectively) are at increased risk of recurrence [10,21]. In
addition, we also demonstrated significant treatment benefits with
proper patient selection. Similar to report by Williams et al, we also
highlight the role of pre-SCT biopsy and its prediction of disease
recurrence [10]. Although a proportion were not included because
of post RT changes making Gleason grading impossible, we found
a trend of increased risk of disease recurrence following SCT in
patients with tumour Gleason score $7. In patients who have had
prior RT, the role of Gleason grade remains controversial.
Currently, the American Society for Therapeutic Radiology and
Oncology does not recommend routine prostate biopsy, but rather
recommends following PSA levels as a marker for recurrent
disease [22]. Finally, we were not able to study for the relationship
between the schedules of previous radiation therapy and
cryotherapy-related toxicities. It will be important to prospectively
collect data on primary radiotherapy as any radiation-induced
injuries are likely to influence tissue response to freezing.
Conclusion
Our data from the largest European series of SCT for radiation
recurrent prostate cancer to date demonstrated acceptable
treatment efficacy and comparable treatment toxicities to
published reports. Importantly, we showed that both the
dimensions of the prostate gland length and the iceball size were
significantly associated with patient IPSS scores.
Table 5. Association between gland length and maximal length of iceball recorded with patient IPSS outcome.
Parameters Mean Std. Dev. n
Multivariate
(Mean IPSS); p values
Multivariate (Max IPSS);
p values
MaxLobe 50.4857 14.6516 35 0.06555 0.05956
Gland_Length 32.6857 3.80226 35 0.00904 7.24E-03
MaxIceball 37.9063 2.93323 32 8.27E-05 8.72E-06
(Max Lobe represents the lowest temperature below 0uC recorded in the prostate; Max Iceball is taken as the longest dimension of iceball recorded for the entire
procedure; n = patient numbers.).
doi:10.1371/journal.pone.0069243.t005
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Supporting Information
Figure S1 Data on pre and post-SCT nadir PSA levels
for each of the three participating centres. (GLA –
Glasgow, SUN – Sunderland, GUIL – Guildford.).
(TIF)
Figure S2 Gleason scores of radiation recurrent pros-
tate cancer prior to SCT are shown for each the three
centres. (GLA – Glasgow, SUN – Sunderland, GUIL –
Guildford.).
(TIF)
Figure S3 Pre and (3-month) post-SCT IPSS levels for
the Glasgow cohort.
(TIF)
Table S1 Summary demographics from the three
participating centres.
(TIF)
Table S2 Breakdown of patient numbers for individual
survival analysis in Figure 2.
(TIF)
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